The Effect of pncA Gene Mutation of Mycobacterium Tuberculosis to Transaminase and Uric Acid Serum in MDR TB Patient
DOI:
https://doi.org/10.36497/jri.v38i3.4Keywords:
pncA gene mutation, MDR TB, PZA, serum transaminase, serum uric acidAbstract
Bacground: The common side effects of PZA treatment is the occurrence of hepatotoxicity and blocking the secretion of uric acid. This study aims to determine the effect of the pncA gene mutation of Mycobacterium tuberculosis to serum transaminase and serum uric acid in patients with MDR TB who had receive therapy with PZA. Methods: Quasi-experimental test was conducted at MDR TB polyclinic in H. Adam Malik Medan Hospital of 25 patients with MDR TB. Mutations of genes was assessed by PCR-RFLP method and data of serum transaminase and serum uric acid retrieved from the medical records, between February until June 2015 Result: Thirtysix percent pncA gene mutation founded. Significance statistic test between mutation of pncA gene and SGOT serum in baseline Vs 4 weeks (P=0,007), baseline Vs 8 weeks (P=0,023) and uric acid serum baseline Vs 4 weeks (P=0,011). No statistically difference in SGPT serum. No correlation between pncA gene (mutation and no mutation) with transaminase serum and uric acid serum. Conclusion: Transaminase serum and uric acid elevated in MDR TB patient with mutation in pncA gene.Mutation in pncA gene have a correlation with elevated SGOT serum compared between baseline, 4 and 8 weeks. No correlation between pncA gene mutation and SGPT. Mutation in pncA gene have a correlation with uric acid serum elevated in 4 weeks. No correlation between pncA gene (mutation and no mutation) with transaminase serum and uric acid serum elevated.Downloads
References
Miquel Q, Andres HG, Robert HG, Cesar L. Structure-activity realtionship in mutated pyrazinamidases from Mycobacterium tuberculosis. Bioinformation. 2011;6:335-9.
Mitchison D, Davies G. The chemotherapy oftuberculosis: past, present and future. Int J Tuberc Lung Dis. 2012;16:724–32.
Ibrahim A, Matteo Z, Dennis F, Mario R, Lucicia D, Susan M, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet
Infect Dis. 2013;13:70030-6.
Mukh S, Sofiati P, Devita T. Deteksi mutasi gen pncA sebagai penyebab resistensi Mycobacterium tuberculosis terhadap pyrazinamid dengan teknik PCR-SSCP dan autografi. Prosiding PPI - PDIPTN 2010 Pustek Akselerator dan Proses Bahan - BATAN Yogyakarta. 2010.p.20-7.
Muthuraj M, Sridharan J, Nisha A, Manupriya S, Sambamurthy SP, Usharani M, et al. Moleculer epidemiological study of pyrazinamide-resistance in clinical isolates of Mycobacterium tuberculosis from South India. Int J Sci. 2010;11:2670-80.
Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Oliver YPH. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother. 2013;57:1685-90.
Zimic M, Patricia F, Gilman RH. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis. 2012;92:84–91.
Momekov G, Dilyan F, Yulian V, Georgi S, Plamen P. Pyrazinamide-phamaceutical, biochemical and pharmalogical properties and reapraisal of its role in the chemotherapy of tuberculosis. Pharmacia. 2014;61.
Fernandes JPS, Pavan FR, Leite CQF, Felli VMA. Synthesis and evaluation of pyrazinoic acid prodrug in Mycobacterium tuberculosis. Saudi Pharm J. 2013;12:005.
Ando H, Mitarai S, Kondo Y, Suetake T, Sekiguchi JI, Kato S, et al. Pyrazinamide resistance in multidrugresistant Mycobacterium tuberculosis in Japan. Clin Microbiol Infect. 2009;16:1164-8.
Tostmann A, Van den Boogaard J, Semvua H. Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Trop Med Int Health. 2010;15:268–72.
Nofizar D, Nawas A, Burhan E. Identifikasi faktor risiko tuberkulosis multidrug resistant (TB-MDR). MKI. 2012;60:537-45.
Rifat M, Milton AH, Hall J. Development of multidrug resistant tuberculosis in Bangladesh: A case-control study on risk factors. Plos One. 2014;9.
Rusdi NK. Gambaran efek samping kombinasi obat dan kesesuaian dosis pada pasien multi drug resistance tuberculosis (TB MDR) di Rumah Sakit Umum Pusat Persahabatan tahun 2010. Farmasi sains. 2011;1
Allahyar Torkaman MR, Sheikholslami FM, Farnia P, Shahhosseiny MH, Mozafari M, Masjedi MR, et al. Study of pncA gene using, PCR-RFLP and Allele-specific PCR methods in Distinguish of Mycobacterium bovis from Mycobacterium tuberculosis. J Res Med Sci. 2011;29:1-8.
Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ,et al. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2012;50(2):428-34.
Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. Systematic analysis of pyrazinamide resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56:5186-93.
Sirait N, Parwati I, Dewi NS, Suraya N. Validitas metode polymerase chain reaction GeneXpert MTB/RIF pada bahan pemeriksaan sputum untuk mendiagnosis multidrug resistant tuberculosis. MKB. 2013;45:234-9.
Annisa F, Fauzi AZ, Fridayenti. Perbedaan kadar SGPT pada pasien tuberkulosis paru sebelum dan sesudah fase intensif di poliklinik paru RSUD Arifin Achmad Pekanbaru. JOM FK. 2015;2:11-9.
Susanty E, Amir Z, Siagian P, Yunita R, Eyanoer PC. Uji Diagnostik GeneXpert MTB/RIF di Rumah Sakit Umum Pusat Haji Adam Malik Medan. Jurnal Biosains. 2015;1:19-30.
World Health Organization. Global tuberculosis report 2013. Geneva: World Health Organization; 2013.p.6-67.
World Health Organization. Rapid implementation of the Xpert MTB/ RIF diagnostic test: technical and operational “How-to” practical consideration. Geneva: World Health Organization; 2014.p.11-8.
Kwok CC, Chi CL, Wing Y, Tat YL, Cheuk MT. Hepatotoxicity of Pyrazinamide. Am J Respir Crit Care Med. 2008;177:1391-6.
Ambreen K, Sharma R, Singh KP, Kumar S. Antituberculosis drug-induced hepatotoxicity. Int J Adv Biotechnol Res. 2014;l5:423-37.
Kusnanto RP, Eko V, Pakiding H, Nurwidiasih D. Multidrug resistant tuberculosis (TB RO): Tinjauan epidemiologi dan faktor risiko efek samping obat anti tuberkulosis. MKB. 2014;4:46-52.
Singla R, Sharma K S, Mohan A. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2009;2010:81-6.
Mpagama SG, Ndusilo N, Stoup S, Kumburu H, Peloquin CA, Gratz J, et al. Plasma drug activity in patients on treatment for multidrug-resistant
tuberculosis. Antimicrob Agents Chemother. 2013; 58:782–8.
Sahota T, Pasqua OD. Feasibility of a fixed dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis. Antimicrob Agents Chemother. 2012;56:5442-9.
Swaroop TVSS, Gowda S. Hepatotoxicity mechanisms and its biomarkers. Int J Pharm Chem Sci. 2012;1:2277-5005.
Downloads
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
